Article
The Usefulness of Metformin and Ganwei for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized, Placebo-Controlled Trial.
International journal of molecular sciences - 5 Mar 2026
Lin Chih-Lin, Li Wei-You, Wu Shang-Jung, Chen Patricia M T, Chen Allan Y, Fann Cathy Shen-Jang, Chen Yi-Ming Arthur
Abstract excerpt
Metabolic dysfunction associated steatotic liver disease (MASLD), a globally prevalent chronic liver disease, has only limited pharmacological options. Both metformin and Ganwei, health supplements containing a potent inducer of glycine N-methyltransferase (GNMT), have shown great promise for the treatment of MASLD. We conducted a 4-arm, randomized, placebo-controlled trial to investigate the safety and efficacy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.